(CSE: $VRT.C), (OTC: $VRTHF) News: US Patent Office Acknowledges Provisional Patent Application for Use of Specific #Cannabis Strain to Enhance Opioid Analgesia

Patent Filed by Veritas’ Research Arm Cannevert

November 28, 2017, Vancouver, B.C. – (Investorideas.com Newswire) Veritas Pharma Inc.(CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. (“CTL”) filed a provisional patent application to US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a specific cannabis strain to enhance the actions of opioid analgesics.  An acknowledgement letter from the USPTO was received recently which provided a filing number of US 62/558,021 for this application.

Read this news in full at http://www.investorideas.com/news/2017/marijuana/11281CannabisCSEVRT.asp

SilverCrest (TSXV: $SIL.V; OTCQX: $SVCMF) Continues to Intercept High-Grade Mineralization at Las Chispas Property, Extensions to Las Chispas and Giovanni Veins

Vancouver, British Columbia - November 28, 2017 (Investorideas.com Newswire) SilverCrest Metals Inc. (TSXV: SIL.V; OTCQX: SVCMF) ("SilverCrest" or the "Company") is pleased to release additional surface and underground drill results from its ongoing Phase II Exploration Program at the Las Chispas Property (the "Property") located in Sonora, Mexico. The surface and underground drill program is designed to define readily accessible high-grade areas in the historic underground workings in the Las Chispas Vein and further define the Giovanni Vein. The Company is currently exploring nine of the 19 known epithermal veins on the Property with efforts focused on four of these veins to be incorporated into SilverCrest's maiden resource estimate anticipated in Q1 2018.

Read this news in full and see images at http://www.investorideas.com/CO/SILV/news/2017/11281LasChispas.asp

This morning, leading medical device maker, Boston Scientific Corp (NYSE:BSX), is trading lower by 4.1 percent. The negative news for the stock is that the company pulled out of a Piper Jaffray Healthcare Conference today. 

Either way, the shares are down and the stock is now trading below its 50 and 100-day moving average. Whenever a stock trades below these critical moving averages it puts the stock in a weak technical position. Traders must now look lower for major chart support. The next major support area would be around the $25.00 level. This area is where the stock broke out in April 2017. Often, when prior break-out levels are tested they will be defended by the institutional money traders. Traders should keep BSX on the radar when it trades around the $25.00 area.